Monday, October 31, 2016
Researchers at the National Institutes of Health have developed a new, less invasive way to perform transcatheter aortic valve replacement (TAVR), a procedure widely used to treat aortic valve stenosis, a lethal heart condition. The new approach, called transcaval access, will make TAVR more available to high risk patients, especially women, whose femoral arteries are too small or diseased to withstand the standard procedure.
Thursday, October 27, 2016
National Institutes of Health researchers have identified a novel role for a gene known as heat shock protein 60 (Hsp60), finding that it is critical in tissue regeneration and wound healing. The study found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model.
Thursday, October 27, 2016
Scientists at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, propose using an assessment tool to diagnose addictive disorders that considers addiction-related behaviors, brain imaging, and genetic data. According to a new review article, the Addictions Neuroclinical Assessment (ANA) would facilitate future understanding of the origin of addiction at a biological level, and could ultimately lead to more effective individualized treatments for addictions. The review appears online in the journal Biological Psychiatry.
Wednesday, October 26, 2016
NIH mouse study could lead to human clinical trials.
For the first time, National Institutes of Health researchers have demonstrated in mice that gene therapy may be the best method for correcting the single faulty gene that causes Niemann-Pick disease, type C1 (NPC1). The gene therapy involved inserting a functional copy of the NPC1 gene into mice with the disease; the treated animals were then found to have less severe NPC1 symptoms.
Wednesday, October 19, 2016
Finding may lead to better therapies for individuals with dust mite allergies.
Scientists from the National Institutes of Health have determined what differentiates dust mite allergens from the non-allergen proteins dust mites produce. According to the researchers, dust mite allergens are more chemically stable and produced in larger quantities than other dust mite proteins.
Monday, October 17, 2016
Previously unexplained symptoms found associated with multiple copies of a single gene.
Scientists at the National Institutes of Health have identified a genetic explanation for a syndrome characterized by multiple frustrating and difficult-to-treat symptoms, including dizziness and lightheadedness, skin flushing and itching, gastrointestinal complaints, chronic pain, and bone and joint problems. Some people who experience these diverse symptoms have elevated levels of tryptase — a protein in the blood often associated with allergic reactions. Multiple copies of the alpha tryptase gene drive these tryptase elevations and may contribute to the symptoms, according to a new study led by investigators at NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
Friday, October 14, 2016
Study with diabetes drug measures how extra calories caused weight loss plateau.
Analysis of a trial that used the drug canagliflozin found that as people lost weight, their appetite increased proportionately, leading to consumption of more calories and weight loss plateau (leveling off). The findings provide the first measurement in people of how strongly appetite counters weight loss as part of the body’s feedback control system regulating weight. Results are currently available on BioRxiv and will publish in Obesity during Obesity Week 2016.
Thursday, October 13, 2016
NIH clinical trial of treatment regimen in HIV-infected people is underway.
Scientists at the National Institutes of Health (NIH) and Emory University have experimentally induced sustained remission of SIV, the simian form of HIV, in infected monkeys. The animals’ immune systems have been suppressing the virus to undetectable levels for as long as 23 months since the monkeys completed an investigational treatment regimen. In addition, the regimen has led to the near-complete replenishment of key immune cells that SIV had destroyed, something unachievable with antiretroviral therapy (ART) alone. The findings will be published in the Oct. 14 issue of the journal Science.
Thursday, October 13, 2016
Trial shows rigorous clinical research feasible during a public health emergency.
A clinical trial to evaluate the experimental Ebola treatment ZMapp found it to be safe and well-tolerated; however, because of the waning Ebola epidemic, the study enrolled too few people to determine definitively whether it is a better treatment for Ebola virus disease (EVD) than the best available standard of care alone. The findings from the randomized, controlled trial known as PREVAIL II appear in the Oct. 13, 2016 issue of The New England Journal of Medicine. Initial trial findings were reported in February 2016, at the Conference on Retroviruses and Opportunistic Infections in Boston.
Monday, September 26, 2016
Comprehensive study confirms earlier reports.
A new analysis by researchers at the National Institutes of Health has provided the strongest evidence to date that nausea and vomiting during pregnancy is associated with a lower risk of miscarriage in pregnant women. The study, appearing in JAMA Internal Medicine, was conducted by researchers at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and other institutions.